TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3511376
Drug: Antacid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid treatment (suspension, 400 mg, one and three hours after meals)
Study: 3511376
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg, twice a day)
Study: 29796595
Drug: Crushed and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed and suspended TRI with oral intake of enteral nutrition
Study: 29796595
Drug: Whole-tablet TRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-tablet TRI with fasting
Study: 22722651
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (15-min infusion)
Study: 22722651
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (30-min infusion)
Study: 22722651
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (60-min infusion)
Study: 22722651
Drug: Oral lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lacosamide (tablet)
Study: 20542574
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n=461)
Study: 19901570
Drug: 90-day Web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-day Web-based treatment program
Study: 11136208
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg diazepam up to three times daily
Study: 9249647
Drug: COX-2 inhibitor
Normalized name: COX-2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 inhibitor (celecoxib)
Study: 7943770
Drug: i.m. MID
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. MID (0.08 mg/kg) and i.v. FENT (MidFent group)
Study: 3107849
Drug: FAM (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM (standard doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Study: 3107849
Drug: Hi-FAM (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hi-FAM (high doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Study: 29508635
Drug: Levothyroxine/liothyronine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine/liothyronine combination therapy
Study: 22305534
Drug: Formula enriched
Normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula enriched with milk fat globule membrane (INPULSE), 200 mL daily for 4 months
Study: 7869208
Drug: Ca gluconate-glycerophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca gluconate-glycerophosphate preparation (group CaGP)
Study: 2374358
Drug: Intensive macrofractional
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive macrofractional irradiation (25 Gr cumulative local dose)
Study: 2374358
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy and surgery with local UHF hyperthermia)
Study: 204971
Drug: INH 5
Normalized name: INH 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH 5 mg/kg body weight + RMP 10 mg/kg body weight + EMB 25 mg/kg body weight daily
Study: 204971
Drug: INH 15
Normalized name: INH 150 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH 15 mg/kg body weight + RMP 10 mg/kg body weight + EMB 40 mg/kg body weight, intermittent administration (2/7)
Study: 3599226
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 150 mg netilmicin sulfate 1 hour preoperatively
Study: 3599226
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1.5 ml of 0.9% sodium chloride 1 hour preoperatively
Study: 31920016
Drug: Oral zabofloxacin
Normalized name: marbofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zabofloxacin for the treatment of COPD exacerbations
Study: 26150070
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (24IU)
Study: 16689000
Drug: Salpingostomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salpingostomy combined with Bushen Huoxue Decoction (BHD), 1 dose every day starting from the 5th day of menstrual cycle for 14 days, with hydrotubation using Xiangdan Injection (XI) applied once in the next menstrual cycle after salpingostomy.
Study: 16689000
Drug: Salpingostomy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salpingostomy alone with hydrotubation using Xiangdan Injection (XI).
Study: 8708654
Drug: Aspirin low
Normalized name: Aspirin Low Dose
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin low dose (< 100 mg per day)
Study: 8708654
Drug: Aspirin medium
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin medium dose (300 to 325 mg per day)
Study: 8708654
Drug: Aspirin high
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin high dose (> 900 mg per day)
Study: 1424410
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg toloxatone three times a day
Study: 1424410
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg toloxatone three times a day
Study: 3936106
Drug: Baclofen (30‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30‐90 mg per day)
Study: 18158708
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ACE inhibitor)
Study: 15122049
Drug: Vaccine 'X'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine 'X'
Study: 10024259
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg or 20 mg daily for 2 weeks
Study: 10024259
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 2 weeks
Study: 10024259
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment overall
Study: 7580003
Drug: Depot leuprorelin
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot leuprorelin (3.75 mg IM injection)
Study: 7580003
Drug: Daily buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buserelin (0.3 mg SC twice daily)
Study: 2134562
Drug: Cimetidine intermittent
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine intermittent infusion (300 mg every 8 hours)
Study: 2134562
Drug: Cimetidine intermittent
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine intermittent infusion (300 mg every 6 hours)
Study: 2134562
Drug: Cimetidine continuous
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine continuous infusion (600 mg per day)
Study: 2134562
Drug: Cimetidine continuous
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine continuous infusion (900 mg per day)
Study: 2134562
Drug: Cimetidine continuous
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine continuous infusion (1200 mg per day)
Study: 6159711
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 6 months
Study: 6159711
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 8 months
Study: 6159711
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by thiacetazone plus isoniazid for 6 months
Study: 6159711
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by twice-weekly streptomycin, isoniazid and pyrazinamide for 6 months
Study: 6159711
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen without pyrazinamide for 2 months followed by thiacetazone plus isoniazid for 6 months
Study: 6140492
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg twice a day for seven days
Study: 6140492
Drug: Single 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 g dose of metronidazole after placebo failure
Study: 6140492
Drug: Recurrence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recurrence of infection after treatment
Study: 30045174
Drug: Overall breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall breast augmentation (both groups)
Study: 26219549
Drug: Face Mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face Mask (FM) therapy with a force of 400g for each side
Study: 26219549
Drug: Skeletal Anchorage
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skeletal Anchorage (SA) therapy with intermaxillary elastics and a force of 200g
Study: 24859491
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg/day)
Study: 20399994
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg (steady state)
Study: 20399994
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg (steady state)
Study: 20399994
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg (steady state)
Study: 9135508
Drug: Idarubicin 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days
Study: 9135508
Drug: Idarubicin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 15 mg/m2 days 1, 2 and 3 and prednimustine 100 mg/m2 days 2-6, every 21 days
Study: 7534946
Drug: Saruplase (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saruplase (20 mg bolus plus 60 mg continuous 1 h i.v. infusion)
Study: 3556262
Drug: Compound analgesic/anti-emetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound analgesic/anti-emetic formulation (paracetamol 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg, dioctyl sodium sulphosuccinate 10 mg) taken as two tablets during acute attack
Study: 29857919
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg)
Study: 29857919
Drug: Rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy (5, 10, and 20 mg)
Study: 26709942
Drug: Modified-live virus
Normalized name: Measles virus vaccine live attenuated
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-live virus vaccines (groups B, C, D, E)
Study: 22867111
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU compounded vitamin D3 capsule monthly)
Study: 22867111
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical inert capsule)
Study: 17574729
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (2mg once daily) for 12 months
Study: 8076917
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid/day
Study: 2692264
Drug: Metronidazole and
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole and ampicillin treatment for one to four days, wounds closed on the fourth day.
Study: 30898323
Drug: Individual female-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual female-specific cognitive behavioral therapy (I-FS-CBT)
Study: 30898323
Drug: Group female-specific
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group female-specific cognitive behavioral therapy (G-FS-CBT)
Study: 26912161
Drug: α-linolenic acid
Normalized name: α-linolenic acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-linolenic acid (ALA) treatment (4.0 g daily for 12 weeks)
Study: 22151299
Drug: Training administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training administered to working mothers on breastfeeding techniques, duration: five home visits starting two weeks before returning to work until infants are six months old.
Study: 17649720
Drug: ATRA +
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA + As4S4 + chemotherapy
Study: 14997024
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition protocols
Study: 7868711
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole twice daily
Study: 7868711
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day itraconazole
Study: 31128221
Drug: Stratified approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified approach using post-trial data from participants taking the drug after trial
Study: 27436028
Drug: Particulate steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particulate steroids
Study: 27436028
Drug: Non-particulate steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-particulate steroids
Study: 25811109
Drug: L-glutamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (25 g)
Study: 25811109
Drug: Whole protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole protein (25 g)
Study: 24014905
Drug: Primaquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (15 mg single oral dose)
Study: 15153172
Drug: Lumiracoxib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 800 mg once daily
Study: 9791684
Drug: Remantadine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remantadine (1.5 mg/kg body weight 3 times a day for 3 days)
Study: 9791684
Drug: Arbidole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbidole (10 mg/kg body weight in 4 portions for 5 days)
Study: 1619184
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (Mg oxide) to bring Mg intake to 8 mg/kg body weight/day
Study: 6442713
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml of 10% Intralipid added to TPN over a period of 12 h (1.8‐2.1 g/kg/day)
Study: 29382803
Drug: Mechanical Thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Thrombectomy After Intravenous Alteplase
Study: 25204642
Drug: Ultrafine carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrafine carbon particles (64 μg/m³; 6.1 ± 0.4 × 10⁵ particles/cm³ for 2 h)
Study: 19578132
Drug: Supervised diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised diet and exercise plus transdermal testosterone (50 mg once daily)
Study: 19578132
Drug: Supervised diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised diet and exercise plus transdermal testosterone
Study: 17538804
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% gel applied twice daily for at least 15 days
Study: 15045047
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg azithromycin daily (high dose)
Study: 15045047
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg azithromycin twice weekly (low dose)
Study: 15045047
Drug: Both high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high and low dose azithromycin
Study: 9889712
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride baths (30 and 50 g/l)
Study: 9889712
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride baths (50 g/l)
Study: 7701577
Drug: OKT3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 (5 mg/d)
Study: 7701577
Drug: ATG-F (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-F (4 mg/kg/d)
Study: 2707058
Drug: Aerosolized metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized metaproterenol delivered by metered‐dose inhaler (MDI) with a spacer device (Aerochamber)
Study: 28378366
Drug: Low patient-centered
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low patient-centered communication (L-PCC) style
Study: 16980741
Drug: Antioxidant agent
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant agent administered into dental tissues after endo bleaching, cavity filled immediately.
Study: 9284858
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day citalopram alone
Study: 9284858
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day citalopram with brief psychosocial intervention
Study: 7890822
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3-0.6 mg/kg/day
Study: 30825414
Drug: Participatory intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participatory intervention using an online social network with weekly posters and active communication with mothers.
Study: 29198191
Drug: Culturally appropriate
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally appropriate multi-faceted oral health promotion intervention including anticipatory guidance, Motivational Interviewing, health and dental care for mothers during pregnancy and children at 6, 12, and 18 months.
Study: 19811918
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide only (C)
Study: 16968397
Drug: IVIg therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg therapy (2 g/kg body weight, monthly for 6 months)
Study: 15164224
Drug: Insulin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (two types) injected subcutaneously
Study: 11001240
Drug: Imipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine at a fixed, targeted, weight‐adjusted dose of 2.25 mg x kg(‐1) x day(‐1)
Study: 8322488
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms dose of influenza vaccine
Study: 8322488
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms dose of influenza vaccine
Study: 8322488
Drug: 60 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 micrograms dose of influenza vaccine
Study: 3964359
Drug: Silver sulfadiazene
Normalized name: SILVER SULFADIAZINE 10 g in 1000 g TOPICAL CREAM [Silver Sulfadiazene]
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazene cream (Silvadene)
Study: 27834743
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment arm
Study: 24605793
Drug: Perampanel 12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 12 mg during the extension blinded Conversion Period (n=217)
Study: 24605793
Drug: Perampanel 12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 12 mg during weeks 1-13 of the extension Maintenance Period (n=181)
Study: 24605793
Drug: Perampanel 12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 12 mg during the extension
Study: 22672363
Drug: Diet high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet high in fibre (>25 g/day)
Study: 22672363
Drug: Diet low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet low in fibre (<25 g/day)
Study: 22672363
Drug: Diet low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet low in fibre (g/day)
Study: 22672363
Drug: Diet low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet low in carbohydrate (g/day)
Study: 18327813
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg orally on Day 1 followed by 80 mg on Days 2-3 (Arm A)
Study: 18327813
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg orally on Day 1 and placebo on Days 2-3 (Arm B)
Study: 6173522
Drug: Captopril 32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 32.5 mg/day
Study: 6173522
Drug: Captopril 75
Normalized name: captopril 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 75 mg/day
Study: 12200983
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day) for 28 days